Cadila Pharmaceuticals Executive and Leadership Team

Ajay Trivedi, the Chief Executive Officer at Cadila Pharmaceuticals, directs the company's overall strategic vision and operational execution. Trivedi guides Cadila Pharmaceuticals' integrated business model, which spans the entire pharmaceutical value chain from API and intermediate manufacturing to finished formulations, over-the-counter products, and advanced biotechnology solutions. This leadership role involves aligning all departmental functions to achieve robust market growth and operational efficiency across India and international markets. Ajay Trivedi ensures that the company's diverse product portfolio, including pharmaceutical machinery, meets stringent quality standards and regulatory requirements. The CEO's purview extends to fostering innovation within the research and development divisions and optimizing manufacturing processes to maintain a competitive edge in the global pharmaceutical landscape. This executive's focus is on driving sustainable expansion and reinforcing Cadila Pharmaceuticals' position as a leading privately held pharmaceutical entity.

Kamalesh Kalidasan, the Chief Operating Officer at Cadila Pharmaceuticals, oversees the day-to-day operational activities and ensures seamless execution of manufacturing and supply chain processes. Kalidasan's responsibilities include optimizing production workflows for APIs, intermediates, and finished formulations, maintaining high standards of quality control, and managing the logistics of product distribution across various regions. This executive drives efficiency improvements within the manufacturing facilities, ensuring adherence to global regulatory compliance and safety protocols. Kamalesh Kalidasan also plays a critical part in integrating new technologies and methodologies to enhance operational output and reduce costs. The Chief Operating Officer's strategic focus is on scaling production capabilities to meet growing market demand and ensuring the reliable supply of Cadila Pharmaceuticals' diverse product range, from biotechnology products to food supplements.

Mitul Dave, the Chief Operating Officer- CSBU at Cadila Pharmaceuticals, manages the operational aspects of the company's core strategic business units, ensuring alignment with overall corporate objectives. Dave's focus is on enhancing the efficiency and effectiveness of operations within these key business segments, which likely encompass critical product lines such as APIs, intermediates, and finished formulations. This executive drives process improvements, optimizes resource allocation, and ensures that production targets are met while maintaining the highest quality standards. Mitul Dave also collaborates with other C-suite leaders to implement strategic initiatives that support Cadila Pharmaceuticals' growth trajectory. The Chief Operating Officer- CSBU's leadership is vital for maintaining operational excellence and ensuring the consistent delivery of high-quality pharmaceutical products to domestic and international markets.

Sanjay Shrivastava, the Global President, Regulatory Affairs at Cadila Pharmaceuticals, directs all aspects of regulatory compliance and strategy on a worldwide scale. Shrivastava ensures that Cadila Pharmaceuticals' diverse product portfolio, including APIs, finished formulations, OTC products, and biotechnology solutions, adheres to the complex and evolving regulatory requirements of different international markets. This leadership role involves managing submissions for product approvals, maintaining compliance with Good Manufacturing Practices (GMP), and liaising with global health authorities. Sanjay Shrivastava's expertise is crucial for navigating the regulatory landscape, facilitating market access, and mitigating compliance risks. The Global President's objective is to uphold the highest standards of product safety and efficacy, thereby safeguarding Cadila Pharmaceuticals' reputation and ensuring uninterrupted market presence.

Madhusudhan Bommagani, the President, Research & Development at Cadila Pharmaceuticals, leads the company's innovation pipeline and scientific advancement initiatives. Bommagani oversees the discovery and development of new pharmaceutical products, including novel drug formulations, biotechnology products, and improved manufacturing processes for APIs and intermediates. This executive fosters a culture of scientific inquiry and collaboration, driving research efforts to address unmet medical needs and enhance existing product lines. Madhusudhan Bommagani ensures that R&D activities align with market trends and regulatory expectations, translating scientific breakthroughs into commercially viable solutions. The President of Research & Development's strategic vision is critical for maintaining Cadila Pharmaceuticals' competitive edge and contributing to the company's long-term growth through groundbreaking pharmaceutical innovations.

Wilton Franca, the President - Latam at Cadila Pharmaceuticals, spearheads the company's strategic initiatives and commercial operations across the Latin American region. Franca is responsible for driving market penetration, expanding the product portfolio's reach, and ensuring compliance with local regulatory frameworks within Latin America. This executive cultivates key relationships with distributors, healthcare providers, and government bodies to strengthen Cadila Pharmaceuticals' presence in this vital market. Wilton Franca oversees sales, marketing, and operational strategies tailored to the unique dynamics of the Latam region, aiming to maximize revenue and market share. The President - Latam's leadership is essential for adapting global strategies to regional needs and achieving sustained business growth in Latin America.

Suresh Balasubramanian, the President - Plantations at Cadila Pharmaceuticals, directs the strategic management and operational oversight of the company's plantation assets. Balasubramanian ensures the efficient cultivation, harvesting, and sustainable management of resources critical to Cadila Pharmaceuticals' integrated operations, potentially supporting the supply chain for certain raw materials or specialized products. This executive focuses on optimizing agricultural yields, implementing best practices in land management, and ensuring environmental compliance. Suresh Balasubramanian's role involves maximizing the productivity and value of these plantation resources, contributing to the overall stability and resource security of the company. The President - Plantations' leadership is key to maintaining a robust and sustainable foundation for specific aspects of Cadila Pharmaceuticals' business.

Prabodh Joshi, the Group President, Human Resources & Corporate Communications at Cadila Pharmaceuticals, leads the strategic development and execution of human capital management and external communications initiatives. Joshi oversees talent acquisition, employee development, organizational culture, and employee relations, ensuring a motivated and skilled workforce across all Cadila Pharmaceuticals' operations. This executive also manages the company's public image, stakeholder engagement, and corporate messaging, reinforcing Cadila Pharmaceuticals' brand identity and values. Prabodh Joshi plays a pivotal role in fostering a positive work environment and ensuring effective communication channels both internally and externally. The Group President's objective is to align human resources strategies with business goals and enhance the company's reputation among employees, investors, and the public.

Raj Vyas, the Group President, Corporate & Public Affairs at Cadila Pharmaceuticals, directs the company's engagement with government bodies, industry associations, and the broader public sphere. Vyas is responsible for shaping public policy positions, managing government relations, and advocating for Cadila Pharmaceuticals' interests on critical industry matters. This executive oversees corporate social responsibility initiatives and ensures the company operates with integrity and transparency. Raj Vyas plays a crucial role in building and maintaining strong relationships with key stakeholders, enhancing Cadila Pharmaceuticals' corporate reputation and social license to operate. The Group President's focus is on navigating the complex external landscape to support the company's strategic objectives and long-term sustainability.

Ranvir Rana, the Head Chief Revenue Officer, Business Development at Cadila Pharmaceuticals, spearheads revenue generation strategies and identifies new business opportunities for market expansion. Rana's role involves cultivating strategic partnerships, negotiating key commercial agreements, and driving sales performance across all product categories, including APIs, finished formulations, and biotechnology products. This executive is instrumental in developing and executing go-to-market plans that enhance Cadila Pharmaceuticals' market penetration and revenue streams. Ranvir Rana also leads the business development initiatives, exploring potential mergers, acquisitions, and licensing opportunities to accelerate company growth. The Chief Revenue Officer's objective is to maximize profitability and secure long-term financial stability by expanding the company's global footprint and diversifying its revenue sources.